Opendata, web and dolomites

Bronchomycn

First in class epithelial Barrier-enhancing medicine for respiratory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Bronchomycn project word cloud

Explore the words cloud of the Bronchomycn project. It provides you a very rough idea of what is the project "Bronchomycn" about.

efficient    200    28    agents    preclinical    barrier    27    mill    epithelium    obstructive    belong    therapeutics    forecast    12    toxins    plan    compounds    2022    near    caused    stem    deaths    2015    epithelial    rodents    sales    world    29    stages    morbidity    continue    save    2026    structurally    hospital    investment    cell    ready    treatment    clinical    usa    decreasing    prepare    turnover    burden    2018    additional       respiratory    class    drug    market    consequence    barriolides    drugs    14    azithromycin    commercialization    2024    decided    24    university    regulatory    economic    copd    disorder    epiendo    ipr    airway    respectively    speed    considering    ebf    million    disease    health    acts    accounted    points    invested    protection    23    807    give    2004    64    organization    infectious    48    commercializing    people    2014    billion    membrane    lacks    49    antibiotic    start    permeability    suffered    vivo    chronic    roi    valued    complications    bronchomycn    medical    2021    pulmonary   

Project "Bronchomycn" data sheet

The following table provides information about the project.

Coordinator
EPI-ENDO PHARMACEUTICALS EHF 

Organization address
address: 28 BORGARTUNI
city: REYKJAVIK
postcode: 105
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Project website http://www.epiendo.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EPI-ENDO PHARMACEUTICALS EHF IS (REYKJAVIK) coordinator 50˙000.00

Map

 Project objective

Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity.

According to the World Health Organization 64 million people suffered COPD in 2004. The EU-28 and USA accounted for 23 and 12.7 million people respectively, which caused near 200,000 deaths. As a consequence of the medical complications of COPD the economic burden has been estimated as € 48.4 and € 29.3 billion in EU-28 and USA respectively

EpiEndo, aims at commercializing a new drug which will be able to save € 27 billion to EU-28 and USA.

Bronchomycn belong to Barriolides, a new class of compounds that provide effective treatment against EBF. Bronchomycn is structurally based on the well-known azithromycin, but lacks antibiotic activity and it acts by decreasing the permeability of the pulmonary epithelium membrane to toxins and infectious agents.

We have been working since 2014 in collaboration with the Stem Cell Research Unit and the University Hospital and now our product is in the early in-vivo stages, for what we have invested € 0.5 Mill. In order to get Bronchomycn to the market, we will start the Clinical studies in 2018 and we expect that current knowledge about side effects of azithromycin speed up the process so that the product will be ready for commercialization in 2021.

During Phase 1 we will prepare the preclinical studies in rodents and clinical studies and defining end-points and regulatory requirements, prepare IPR protection plan, etc.

The market for Bronchomycn is the respiratory therapeutics market which was valued at € 24.8 billion in 2015. We plan to start our sales in Europe in 2022 and USA in 2024, so that by 2026 our turnover will reach €807 Mill.

Therefore, we have decided to continue with Bronchomycn for what we need an additional investment of € 49 Mill, that considering a 5-years forecast will give us a ROI of 14.2

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRONCHOMYCN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRONCHOMYCN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More